Aligos Therapeutics (ALGS) Operating Expenses (2019 - 2026)

Aligos Therapeutics (ALGS) has reported Operating Expenses for 8 consecutive years, with $29.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 51.89% year-over-year to $29.7 million; the trailing twelve-month figure through Jun 2026 stood at $110.5 million (up 35.3% YoY), and the FY2025 full-year result was $90.2 million, down 3.15% from the prior year.
• Operating Expenses held at $29.7 million in Q2 2026 per ALGS's latest filing, from $29.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $38.1 million in Q1 2022 and bottomed at $19.5 million in Q2 2025.
• Historically, Operating Expenses has averaged $25.4 million across 5 years, with a median of $25.1 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Operating Expenses sank 33.38% in 2022, then surged 52.19% in 2026.
• Over 5 years, Operating Expenses stood at $26.2 million in 2022, then climbed by 9.38% to $28.7 million in 2023, then retreated by 26.1% to $21.2 million in 2024, then advanced by 3.73% to $22.0 million in 2025, then soared by 34.96% to $29.7 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $29.7 million, $29.8 million, and $22.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.